465 GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB)
Journal of Investigative Dermatology（2022）
关键词
dystrophic epidermolysis bullosa,topical beremagene therapy,immunogenicity results,beremagene geperpavec,b-vec
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要